SK6212003A3 - Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia - Google Patents

Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia Download PDF

Info

Publication number
SK6212003A3
SK6212003A3 SK621-2003A SK6212003A SK6212003A3 SK 6212003 A3 SK6212003 A3 SK 6212003A3 SK 6212003 A SK6212003 A SK 6212003A SK 6212003 A3 SK6212003 A3 SK 6212003A3
Authority
SK
Slovakia
Prior art keywords
ldl
patient
patients
cholesterol
methylsulfonyl
Prior art date
Application number
SK621-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Ali Raza
Howard Gerard Hutchinson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK6212003(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SK6212003A3 publication Critical patent/SK6212003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK621-2003A 2000-11-22 2001-11-16 Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia SK6212003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy
PCT/GB2001/005041 WO2002041895A1 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Publications (1)

Publication Number Publication Date
SK6212003A3 true SK6212003A3 (en) 2003-11-04

Family

ID=9903629

Family Applications (1)

Application Number Title Priority Date Filing Date
SK621-2003A SK6212003A3 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia

Country Status (35)

Country Link
US (1) US6858618B2 (es)
EP (1) EP1339409B1 (es)
JP (2) JP5062940B2 (es)
KR (1) KR100815042B1 (es)
CN (1) CN1268339C (es)
AR (1) AR031766A1 (es)
AT (1) ATE394103T1 (es)
AU (2) AU2002214165B9 (es)
BG (1) BG66009B1 (es)
BR (1) BR0115511A (es)
CA (1) CA2429263C (es)
CY (1) CY1110428T1 (es)
CZ (1) CZ301583B6 (es)
DE (1) DE60133921D1 (es)
DK (1) DK1339409T3 (es)
EE (1) EE05507B1 (es)
ES (1) ES2305118T3 (es)
GB (1) GB0028429D0 (es)
HK (1) HK1056691A1 (es)
HU (1) HUP0301380A3 (es)
IL (2) IL155919A0 (es)
IS (1) IS6819A (es)
MX (1) MXPA03004336A (es)
MY (1) MY134902A (es)
NO (1) NO326245B1 (es)
NZ (1) NZ525754A (es)
PL (1) PL365386A1 (es)
PT (1) PT1339409E (es)
RU (1) RU2294744C2 (es)
SI (1) SI1339409T1 (es)
SK (1) SK6212003A3 (es)
TW (1) TWI238720B (es)
UA (1) UA75614C2 (es)
WO (1) WO2002041895A1 (es)
ZA (1) ZA200303636B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
AU2004233897A1 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7396927B2 (en) * 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
EP1689723B1 (en) * 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Reference standard for characterization of rosuvastatin
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
KR20070088324A (ko) * 2004-05-26 2007-08-29 케이지케이 시너자이즈 인코포레이티드 플라보노이드 및 토코트리에놀을 포함하는 기능성 식품 및그에따른 방법
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
ATE505196T1 (de) 2004-07-27 2011-04-15 Gilead Sciences Inc Nukleosid phosphonat konjugate als anti hiv mittel
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
KR100945763B1 (ko) * 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 제조 방법
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
KR20070062996A (ko) * 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
US8653265B2 (en) 2008-05-27 2014-02-18 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
ES2393962T3 (es) 2008-07-08 2013-01-03 Gilead Sciences, Inc. Sales de compuestos inhibidores del VIH.
SG10202006058QA (en) 2012-09-17 2020-08-28 Madrigal Pharmaceuticals Inc Method of synthesizing thyroid hormone analogs and polymorphs thereof
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
ES2969496T3 (es) 2017-08-01 2024-05-20 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
US11975025B2 (en) 2019-05-27 2024-05-07 Immatics US, Inc. Viral vectors and use thereof in adoptive cellular therapy
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
MX2023009024A (es) * 2021-02-01 2023-08-09 Madrigal Pharmaceuticals Inc Combinaciones terapeuticas de rosuvastatina y resmetirom para el tratamiento de trastornos hepaticos o trastornos lipidicos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2423335C (en) * 2000-09-20 2011-03-01 Rtp Pharma Inc. Spray drying process and compositions of fenofibrate

Also Published As

Publication number Publication date
KR20030048479A (ko) 2003-06-19
WO2002041895A1 (en) 2002-05-30
ES2305118T3 (es) 2008-11-01
NO326245B1 (no) 2008-10-27
HUP0301380A3 (en) 2007-03-28
CY1110428T1 (el) 2015-04-29
NZ525754A (en) 2004-10-29
DE60133921D1 (de) 2008-06-19
JP5062940B2 (ja) 2012-10-31
NO20032292L (no) 2003-07-17
BR0115511A (pt) 2003-12-30
CZ20031406A3 (cs) 2003-09-17
CA2429263C (en) 2009-03-17
UA75614C2 (uk) 2006-05-15
CA2429263A1 (en) 2002-05-30
MY134902A (en) 2007-12-31
RU2294744C2 (ru) 2007-03-10
CN1630520A (zh) 2005-06-22
JP2004522714A (ja) 2004-07-29
HUP0301380A2 (hu) 2003-10-28
KR100815042B1 (ko) 2008-03-18
CZ301583B6 (cs) 2010-04-21
ATE394103T1 (de) 2008-05-15
DK1339409T3 (da) 2008-09-08
BG107811A (bg) 2004-03-31
PL365386A1 (en) 2005-01-10
AU2002214165B9 (en) 2013-07-04
AR031766A1 (es) 2003-10-01
JP2010031047A (ja) 2010-02-12
EE200300239A (et) 2003-08-15
NO20032292D0 (no) 2003-05-21
AU1416502A (en) 2002-06-03
ZA200303636B (en) 2004-08-12
GB0028429D0 (en) 2001-01-10
US6858618B2 (en) 2005-02-22
AU2002214165B2 (en) 2006-12-14
SI1339409T1 (sl) 2008-08-31
IL155919A (en) 2009-09-01
TWI238720B (en) 2005-09-01
IS6819A (is) 2003-05-19
EP1339409B1 (en) 2008-05-07
MXPA03004336A (es) 2003-08-19
HK1056691A1 (en) 2004-02-27
CN1268339C (zh) 2006-08-09
EP1339409A1 (en) 2003-09-03
IL155919A0 (en) 2003-12-23
EE05507B1 (et) 2012-02-15
US20040072852A1 (en) 2004-04-15
BG66009B1 (bg) 2010-10-29
PT1339409E (pt) 2008-07-07

Similar Documents

Publication Publication Date Title
SK6212003A3 (en) Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia
AU2002214165A1 (en) Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia
US5260305A (en) Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
JP2014065718A (ja) 糖尿病性神経障害の治療用医薬品を製造するための３−ヒドロキシ−３−メチルグルタリル補酵素ａレダクターゼ阻害剤の使用
JP2011137023A (ja) コレステロール低下薬の使用
US20070197602A1 (en) Combined pharmaceutical composition
US20030060477A1 (en) Combination of a betablocker and a cholesterol-lowering agent
US20040087597A1 (en) Preventives and remedies for complications of diabetes
NZ501844A (en) Alkanoyl L-carnitine in combination with a statin (simvastatin, lovastatin, provastatin or fluvastatin) for treating abnormal lipid metabolism disorders
JP4409295B2 (ja) Ｐｔｘ３遺伝子発現抑制方法
JP2002518448A (ja) 高血中コレステロールを治療する組成物および方法
JP4187141B2 (ja) 新規なトロンボモジュリン発現促進剤
EP1296716B1 (en) Use of a beta-blocker for the treatment of atherosclerosis
Shimpi et al. Bempedoic acid a novel drug used for the treatment of Hyperlipidaemia: A Review
WO2002020009A1 (fr) Compositions medicales
MXPA99011665A (es) Composiciones farmaceuticas que comprenden alcanoil l-carnitina en combinacion con una estatina para tratar patologias causadas por un metabolismo alterado del lipido

Legal Events

Date Code Title Description
FC9A Refused patent application